Intelligent Bio Solutions (INBS) Total Non-Current Liabilities (2023)
Intelligent Bio Solutions' quarterly Total Non-Current Liabilities came in at $5.7 million in Q4 2023, down 14.81% quarter-over-quarter from $6.7 million in Q2 2023.
Intelligent Bio Solutions has reported Total Non-Current Liabilities for 1 years, with the latest figure at $5.7 million in Q4 2023.
- For the quarter ending Q4 2023, Total Non-Current Liabilities changed N/A year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2023 stood at $5.7 million (changed N/A YoY), and the FY2023 full-year result was $6.7 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2023 stood at $5.7 million, down from $6.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $6.7 million in Q2 2023, with the low at $5.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Intelligent Bio Solutions | 13.61 Mn | 12.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5.67 Mn |
| Jun 30, 2023 | 6.66 Mn |